1. Home
  2. SAR vs LCTX Comparison

SAR vs LCTX Comparison

Compare SAR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

BUY

Current Price

$15.14

Market Cap

233.9M

Sector

Finance

ML Signal

BUY

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$0.95

Market Cap

251.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
LCTX
Founded
2007
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.9M
251.4M
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
SAR
LCTX
Price
$15.14
$0.95
Analyst Decision
Hold
Strong Buy
Analyst Count
7
7
Target Price
★ $20.00
$5.50
AVG Volume (30 Days)
164.2K
★ 1.5M
Earning Date
10-06-2026
11-05-2026
Dividend Yield
★ 19.58%
N/A
EPS Growth
★ 14.36
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $14,556,000.00
Revenue This Year
$0.78
$4.38
Revenue Next Year
$6.28
$10.80
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 53.24
52 Week Low
$13.78
$0.88
52 Week High
$24.07
$2.09

Technical Indicators

Market Signals
Indicator
SAR
LCTX
Relative Strength Index (RSI) 29.38 46.61
Support Level $13.78 $0.88
Resistance Level $23.85 $1.18
Average True Range (ATR) 0.53 0.06
MACD -0.02 0.01
Stochastic Oscillator 38.03 45.61

Price Performance

Historical Comparison
SAR
LCTX

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: